Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.
Arcellx has raised $200.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2023.
Arcellx's investors include Samsara BioCapital, New Enterprise Associates, Sixty Degree Capital, Novo Holdings, SR One.
Arcellx is headquartered in Redwood City, United States.
Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.
Arcellx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arcellx — Funding & Investors." VCBacked, November 15, 2023, https://www.vcbacked.co/company/arcellx. Accessed November 14, 2026.
VCBacked. (2023). Arcellx — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/arcellx
{{cite web |title=Arcellx — Funding & Investors |url=https://www.vcbacked.co/company/arcellx |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Arcellx? Request a listing update